newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Seeking Alpha
Bristol Myers multiple myeloma drug improves survival by 50% in late-stage study.
Bristol Myers' mezigdomide improved cancer-free survival by over 50% in a late-stage myeloma trial.
KEY POINTS
Mezigdomide was tested as part of a combination regimen for multiple myeloma.
This result comes from a late-stage, or Phase 3, clinical trial.
Mezigdomide is an antitumor candidate specifically developed for multiple myeloma treatment.
Bristol Myers multiple myeloma drug improves survival by 50% in late-stage study
May 29, 2026, 9:09 AM ETBristol-Myers Squibb Company (BMY) StockKDBy : Dulan Lokuwithana, SA News Editor
Comments
(2)
Bristol Myers Squibb (BMY) announced on Friday that its antitumor candidate mezigdomide, as part of a combination regimen, improved cancer-free survival by more than 50% in a late-stage trial for multiple myeloma, a type of blood cancer.
Citing data from
Newsletters for Every Investor
Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities.
Subscribe to Newsletters